Tags

Type your tag names separated by a space and hit enter

GABAA-benzodiazepine-chloride receptor-targeted therapy for tinnitus control: preliminary report.
Int Tinnitus J. 2002; 8(1):30-6.IT

Abstract

Our goal was to attempt to establish neuropharmacological tinnitus control (i.e., relief) with medication directed to restoration of a deficiency in the gamma-aminobutyric acid-benzodiazepine-chloride receptor in tinnitus patients with a diagnosis of a predominantly central type tinnitus. Thirty tinnitus patients completed a medical audiological tinnitus patient protocol and brain magnetic resonance imaging and single-photon emission computed tomography of brain. Treatment with GABAergic and benzodiazepine medication continued for 4-6 weeks. A maintenance dose was continued when tinnitus control was positive. Intake and outcome questionnaires were completed. Of 30 patients, 21 completed the trial (70%). Tinnitus control lasting from 4-6 weeks to 3 years was reported by 19 of the 21 (90%). The trial was not completed by 9 of the 30 (30%). No patient experienced an increase in tinnitus intensity or annoyance. Sequential brain single-photon emission computed tomography in 10 patients revealed objective evidence of increased brain perfusion. Patients with a predominantly central type tinnitus experience significant tinnitus control with medication directed to the gamma-aminobutyric acid-benzodiazepine-chloride receptor.

Authors+Show Affiliations

Martha Entenmann Tinnitus Research Center, Health Science Center at Brooklyn, State University of New York, Box 1239, 450 Clarkson Avenue, Brooklyn, NY 11203, USA. metrc@inch.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14763233

Citation

Shulman, Abraham, et al. "GABAA-benzodiazepine-chloride Receptor-targeted Therapy for Tinnitus Control: Preliminary Report." The International Tinnitus Journal, vol. 8, no. 1, 2002, pp. 30-6.
Shulman A, Strashun AM, Goldstein BA. GABAA-benzodiazepine-chloride receptor-targeted therapy for tinnitus control: preliminary report. Int Tinnitus J. 2002;8(1):30-6.
Shulman, A., Strashun, A. M., & Goldstein, B. A. (2002). GABAA-benzodiazepine-chloride receptor-targeted therapy for tinnitus control: preliminary report. The International Tinnitus Journal, 8(1), 30-6.
Shulman A, Strashun AM, Goldstein BA. GABAA-benzodiazepine-chloride Receptor-targeted Therapy for Tinnitus Control: Preliminary Report. Int Tinnitus J. 2002;8(1):30-6. PubMed PMID: 14763233.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - GABAA-benzodiazepine-chloride receptor-targeted therapy for tinnitus control: preliminary report. AU - Shulman,Abraham, AU - Strashun,Arnold M, AU - Goldstein,Barbara A, PY - 2004/2/7/pubmed PY - 2004/2/28/medline PY - 2004/2/7/entrez SP - 30 EP - 6 JF - The international tinnitus journal JO - Int Tinnitus J VL - 8 IS - 1 N2 - Our goal was to attempt to establish neuropharmacological tinnitus control (i.e., relief) with medication directed to restoration of a deficiency in the gamma-aminobutyric acid-benzodiazepine-chloride receptor in tinnitus patients with a diagnosis of a predominantly central type tinnitus. Thirty tinnitus patients completed a medical audiological tinnitus patient protocol and brain magnetic resonance imaging and single-photon emission computed tomography of brain. Treatment with GABAergic and benzodiazepine medication continued for 4-6 weeks. A maintenance dose was continued when tinnitus control was positive. Intake and outcome questionnaires were completed. Of 30 patients, 21 completed the trial (70%). Tinnitus control lasting from 4-6 weeks to 3 years was reported by 19 of the 21 (90%). The trial was not completed by 9 of the 30 (30%). No patient experienced an increase in tinnitus intensity or annoyance. Sequential brain single-photon emission computed tomography in 10 patients revealed objective evidence of increased brain perfusion. Patients with a predominantly central type tinnitus experience significant tinnitus control with medication directed to the gamma-aminobutyric acid-benzodiazepine-chloride receptor. SN - 0946-5448 UR - https://www.unboundmedicine.com/medline/citation/14763233/GABAA_benzodiazepine_chloride_receptor_targeted_therapy_for_tinnitus_control:_preliminary_report_ L2 - http://www.diseaseinfosearch.org/result/9653 DB - PRIME DP - Unbound Medicine ER -